Fractyl Health Reports One-Year Weight Maintenance Following Revita Procedure in Post-GLP-1 Patients

Fractyl Health released one-year data from its REVEAL-1 open-label study on Thursday, reporting that patients maintained weight loss for 12 months following a single Revita procedure. The study tracked participants who had previously utilized GLP-1 receptor agonist therapy, observing their ability to sustain weight management outcomes after undergoing the endoscopic treatment.

The REVEAL-1 trial evaluated the durability of the Revita procedure, a device-based intervention designed to modify the lining of the small intestine. According to the data, patients who completed the procedure maintained their weight levels throughout the one-year follow-up period. The study specifically monitored individuals who had transitioned off GLP-1 medications, assessing whether the procedure provided a sustained metabolic effect. Fractyl Health officials noted that these findings represent the completion of the one-year observation window for the open-label cohort, providing a longitudinal look at how the procedure impacts weight maintenance in a post-GLP-1 clinical setting.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 4, 2026

Author

GOAI